Correlation Between SAB Biotherapeutics and Eyepoint Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both SAB Biotherapeutics and Eyepoint Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SAB Biotherapeutics and Eyepoint Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between SAB Biotherapeutics and Eyepoint Pharmaceuticals, you can compare the effects of market volatilities on SAB Biotherapeutics and Eyepoint Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SAB Biotherapeutics with a short position of Eyepoint Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of SAB Biotherapeutics and Eyepoint Pharmaceuticals.

Diversification Opportunities for SAB Biotherapeutics and Eyepoint Pharmaceuticals

0.56

Correlation Coefficient

SAB Biotherapeutics  Eyepoint Pharmaceuticals

Very weak diversification

The 3 months correlation between SAB and Eyepoint is 0.56. Overlapping area represents the amount of risk that can be diversified away by holding SAB Biotherapeutics and Eyepoint Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eyepoint Pharmaceuticals and SAB Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SAB Biotherapeutics are associated (or correlated) with Eyepoint Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eyepoint Pharmaceuticals has no effect on the direction of SAB Biotherapeutics i.e., SAB Biotherapeutics and Eyepoint Pharmaceuticals go up and down completely randomly.

Pair Corralation between SAB Biotherapeutics and Eyepoint Pharmaceuticals

Given the investment horizon of 90 days SAB Biotherapeutics is expected to generate 2.32 times more return on investment than Eyepoint Pharmaceuticals. However, SAB Biotherapeutics is 2.32 times more volatile than Eyepoint Pharmaceuticals. It trades about -0.02 of its potential returns per unit of risk. Eyepoint Pharmaceuticals is currently generating about -0.07 per unit of risk. If you would invest  293.00  in SAB Biotherapeutics on December 3, 2024 and sell it today you would lose (122.00) from holding SAB Biotherapeutics or give up 41.64% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

SAB Biotherapeutics  vs.  Eyepoint Pharmaceuticals

SAB Biotherapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days SAB Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's fundamental drivers remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Eyepoint Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Eyepoint Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with SAB Biotherapeutics and Eyepoint Pharmaceuticals

The main advantage of trading using opposite SAB Biotherapeutics and Eyepoint Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SAB Biotherapeutics position performs unexpectedly, Eyepoint Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eyepoint Pharmaceuticals will offset losses from the drop in Eyepoint Pharmaceuticals' long position.

The idea behind SAB Biotherapeutics and Eyepoint Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.